Thiarabine- and thiarabine prodrug-based treatments
The present disclosure is concerned with combination therapies that include sulfur-based nucleotide and nucleoside compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
1 . A method for treating colorectal cancer in a subject, the method comprising administering to the subject an effective amount of:
(a) a sulfur-based nucleoside or a sulfur-based nucleotide having a structure represented by a formula selected from:
and
(b) Keytruda® (pembrolizumab), thereby treating the colorectal cancer.
2 . The method of claim 1 , wherein the sulfur-based nucleoside or the sulfur-based nucleotide has a structure represented by a formula:
3 . The method of claim 1 , wherein the sulfur-based nucleoside is:
4 . The method of claim 1 , wherein the effective amount is an individually effective amount of the sulfur-based nucleoside or the sulfur-based nucleotide.
5 . The method of claim 1 , wherein the effective amount is a combinatorically effective amount of the sulfur-based nucleoside or the sulfur-based nucleotide and Keytruda® (pembrolizumab), together.
6 . A pharmaceutical composition comprising a therapeutically effective amount of:
(a) a sulfur-based nucleoside or a sulfur-based nucleotide having a structure represented by a formula selected from:
and
(b) Keytruda® (pembrolizumab); and
(c) a pharmaceutically acceptable carrier.
7 . The composition of claim 6 , wherein the effective amount is an individually effective amount of the sulfur-based nucleoside or the sulfur-based nucleotide.
8 . The composition of claim 6 , wherein the effective amount is a combinatorically effective amount of the sulfur-based nucleoside or the sulfur-based nucleotide and Keytruda® (pembrolizumab), together.
9 . The pharmaceutical composition of claim 6 , wherein the sulfur-based nucleoside or the sulfur-based nucleotide has a structure represented by a formula:
10 . The pharmaceutical composition of claim 6 , wherein the sulfur-based nucleoside is: